Key Takeaways
- Revenue grew 20.2% CC YoY, but U.K. softness and NHS uncertainty weighed: Strong Middle East execution and U.S. order book momentum were offset by fewer U.K. working days, deal delays, and continued NHS challenges.
- BizAnalytica acquisition adds data cloud muscle: The ~$16M revenue data modernization specialist brings IP, healthcare and financial services clients, and a path to nonlinear managed services revenue.
- Margins dipped on acquisition-related increments, with a 17-19% full-year range reaffirmed: EBITDA margin fell 20 bps QoQ to 17.5% as Salesforce team increments hit; management expects Q3/Q4 recovery after a possible Q2 blip.
- Order book is mixed but U.S. momentum is building: U.S. bookings hit 1.5x revenue, and a West Coast SI replacement win signals competitive progress, though decision-making delays persist across markets.
- What to watch next quarter: Whether the promised strong QoQ and YoY growth materializes, if NHS shows signs of bottoming, and how quickly BizAnalytica integrates and scales.
Demand Environment & Order Book
- U.K. slowed by holidays and aggressive competition: Fewer working days from Easter and other holidays hit T&M engagements, while cost-optimization deals faced intensified pricing pressure, particularly in the public sector.
- U.S. orders outpaced revenue, setting up Q2 conversion: The order book reached 1.5x revenue, with deals taking longer to close but expected to impact Q2, Q3, and beyond.
- Middle East bet is paying off: A strategic shift of investment from non-U.K. Europe into the Middle East and Australia, driven by funding flows into UAE and Saudi Arabia, is producing strong growth from prior-quarter order book conversion.
- Deal delays and right-shifting persist: Decision-making slowdowns affected Oracle Cloud and other discretionary projects, though transformation and cost-savings initiatives are still getting funded.
- Account mining replaces hunting in key markets: The company reduced its Middle East account footprint to focus on deeper mining, and the U.K. private sector strategy shifted toward mining existing relationships after mixed hunting results.
Chandrana: "The competition has gotten much more aggressive and this is not necessarily a U.K. public sector specific comment, but there's definitely going to be much more aggressive pricing pressure on some of the deals, particularly the cost optimization type of deals."
BizAnalytica Acquisition
- Thesis: data modernization is following the infrastructure and application migration playbook: Management sees the data cloud space undergoing the same shift that infrastructure and applications experienced over the last 15-20 years, and BizAnalytica positions Mastek to capture it.
- Brings IP and managed services potential: The Lightbeam IP for data factory managed services offers a nonlinear revenue opportunity, while expanding offshore delivery from Chennai can improve margins as the business scales.
- Client base spans healthcare, asset management, and retail: BizAnalytica works with Fortune 1000 and Fortune 100 accounts including Optum (UnitedHealth), and brings a reasonable spread across financial services, healthcare, technology, and retail verticals.
- Earnout ties payout to growth and Mastek-level profitability: Sellers earn their upside only if they hit growth targets and deliver margins at Mastek's level, aligning incentives post-close.
- Joint bids already underway: The combined entity has started working under mutual NDAs in one or two accounts, with opportunities to cross-sell Mastek services into BizAnalytica accounts and vice versa.
Chandrana: "If you look at what's happening in the data cloud space. What happened in the infrastructure space and what happened in the application space in the last 15-20 years is really what's happening in the data space."
Vertical & Geographic Performance
| Vertical / Geography | Trend | Commentary |
|---|---|---|
| Middle East | ▲ Strong growth | Strategic investment shift paying off; order book conversion from prior quarters drove results; full-year growth expected faster than Mastek average. |
| U.S. Americas | ▲ Building momentum | Order book at 1.5x revenue; Salesforce revenue muted in Q1 but expected to pick up in Q2; replaced a top-3 Indian SI at a West Coast account. |
| U.K. Public Sector | ▼ Soft | Fewer working days impacted T&M revenue; marquee programs in digital identity and defense continue; pipeline remains strong. |
| U.K. Private Sector | ▬ Mixed | New CIOs and relationship-building slowed progress; short-term focus on mining existing accounts, then opening new logos in Fintech. |
| Healthcare | ▼ Declined | NHS uncertainty and challenges drove the decline; three new wins in Americas healthcare and Middle East wins provide offset; NHS expected to bottom during the year. |
| Oracle Commerce/CX | ▼ Impacted | Oracle deprioritized the space 6-9 months ago; team neutralized impact by shifting to managed services and alternative alliances; no further impact expected. |
- Blue Cross Blue Shield account on track for $10M: A second Blues plan could replicate the model, adding a material U.S. healthcare growth vector.
- U.S. margin trajectory tied to scale: Investments in the geography are already made; as revenue grows, margins should improve quarter-by-quarter, aided by exiting low-potential sub-$1M accounts.
Margins
- Q1 margin dip was acquisition-driven, not operational: EBITDA margin fell 20 bps QoQ to 17.5%, primarily because Salesforce (MST) acquisition team increments effective April hit the P&L, partially offset by currency and operating levers.
- Utilization improved 380 bps including trainees: Better resource utilization and bench balancing provided an operational offset to the increment headwind.
- Full-year range of 17-19% reaffirmed, with a Q2 caveat: Increments in Q2 may cause a transitory blip, but Q3 and Q4 are expected to return to the range.
- BizAnalytica starts at low-double-digit EBITDA, scales to Mastek level: As the acquisition integrates and grows, margins are expected to converge toward Mastek's corporate average.
- PPA amortization typical at 2-3% of acquisition price: More detail promised once September numbers are reported.
Competitive Position & Deal Dynamics
- Being number two in large deals is a stated frustration: Management acknowledged the pain of close losses and is treating conversion as a challenge, with potential to win some of those deals in the current and next quarter.
- One large U.K. deal won last week: A notified win supports the near-term pipeline conversion narrative.
- West Coast SI replacement signals competitive progress: Mastek displaced a top-3 Indian-based SI for a strategic data warehousing and BI deal, demonstrating growing credibility in larger pursuits.
- Oracle Health/Cerner progress opens new angles: Engagement with the Cerner team and Oracle is creating more holistic propositions in select markets.
Chandrana: "But being number 2 in some of those losses is not fun. So we are taking that up as a challenge, and we feel that there is potential to win some of those deals in the current quarter and the next."
Capital Allocation & M&A Strategy
- No near-term acquisitions planned: Management believes capabilities are rounded off for the immediate future, though a 3-4 year model contemplates 4-5 total acquisitions, potentially including U.K. targets.
- Cash position sufficient for working capital and debt repayment: Gross cash of INR 220 crores plus ongoing generation covers near-term needs without strain.
- BizAnalytica was the priority, now integration takes focus: The acquisition closed and joint work has begun; the earnout structure and offshore expansion opportunity make integration execution the near-term value driver.
Chandrana: "We don't plan any other nearterm acquisitions. We believe that we have rounded off the capabilities that is required in the immediate future."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | Strong QoQ and YoY growth; aim to beat industry growth by a few percentage points | From Q2 and for rest of FY24 |
| U.S. Americas growth | Catch up in Q2, get back on track in Q3 for anticipated YoY growth rate | Q2/Q3 FY24 |
| EBITDA margin | 17% to 19% range for full year; Q3 and Q4 return to range after possible Q2 blip | Full year FY24 |
| NHS bottom | Expect to see a bottom and start picking up | Sometime during the year |
| BizAnalytica growth | Grow significantly higher than Mastek's average growth rate | Ongoing |
| Middle East / AMEA growth | Grow faster than Mastek average on a full-year basis | Full year FY24 |
| Salesforce (Americas) revenue | Pick up in Q2 and deliver a good full year | Q2 and full year FY24 |
Key Metrics
| Metric | Q1 FY24 |
|---|---|
| Operating revenue | ₹725 cr, +27.2% YoY and +2.3% QoQ in INR terms; +20.2% YoY and +0.4% QoQ in constant currency |
| Operating EBITDA margin | 17.5%, down 20 bps QoQ; wage hikes for MST partially offset by currency and operating levers |
| PAT | ₹73.5 cr, up 1.3% QoQ |
| 12-month order backlog | $215 mn, +16.9% YoY, -1.7% QoQ in INR terms |
| U.S. Q1 order book to revenue ratio | ~1.5x revenue in that geography |
| Middle East revenue growth | +67% YoY and +34% QoQ |
| Cash and equivalents | ₹220 cr at end of June vs ₹270 cr in March '23 |
| Borrowings | ₹363 cr as of June 30, 2023 |
| Headcount | 5,592, net reduction of 30 QoQ |
| Utilization | Improved by 380 bps QoQ including trainees |
| Clients added | 22 across verticals and geographies |
| BizAnalytica last 12 months revenue | ~$16 mn |
| BizAnalytica expected margin post-integration | Early teens operating EBITDA, up from single digits pre-acquisition |
| Wage hike impact on overall EBITDA | 0.5% to 0.6% drag |